Article information
Abstract
The R3i Foundation (Residual Risk Reduction Initiative), an independent, multinational and academic organization, is conducting the REALIST (Residual Risk, Lipids and Standard Therapies) study in 40 centers in different countries. This is a retrospective epidemiological study, designed to provide new data on the residual risk of major coronary events attributable to lipid abnormalities in patients receiving the current standard treatment. The initial results are expected in mid 2010, and the overall results at the end of 2010.
Keywords:
Residual risk
Dyslipidemia
Ischemic heart disease
Resumen
La Fundación R3i (Residual Risk Reduction initiative), una organización académica, multinacional e independiente, está llevando a cabo el estudio REALIST (REsidual risk, LIpids and Standard Therapies) en más de 40 centros de diferentes países. Se trata de un estudio epidemiológico retrospectivo, que está diseñado para proporcionar nuevos datos referentes al riesgo residual de episodios coronarios mayores atribuible a las alteraciones lipídicas en pacientes que reciben los tratamientos de referencia actuales. Sus resultados iniciales se esperan para mediados del año 2010, y los resultados globales para finales del año 2010.
Palabras clave:
Riesgo residual
Dislipemia
Cardiopatía isquémica
Full text is only aviable in PDF
References
[1.]
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)..
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report.
Circulation, 106 (2002), pp. 3143-3421
[2.]
Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.
European guidelines on cardiovascular disease prevention in clinical practice. Executive summary.
EHJ, 28 (2007), pp. 2375-2414
[3.]
S.C. Smith Jr, J. Allen, S.N. Blair, R.O. Bonow, L.M. Brass, G.C. Fonarow, et al.
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update.
Circulation, 113 (2006), pp. 236-272
[4.]
J.B. Buse, H.N. Ginsberg, G.L. Bakris, N.G. Clark, F. Costa, R. Eckel, American Diabetes Association, et al.
Primary prevention of cardiovascular diseases in people with diabetes mellitus. A Scientific Statement from the American Heart Association and the American Diabetes Association.
Circulation, 115 (2007), pp. 114-126
[5.]
American Diabetes Association.
Standards of medical care in diabetes-2008.
Diabetes Care, 31 (2008), pp. S12-S54
[6.]
L. Rydén, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.J. De Boer, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary.
Eur Heart J, 28 (2007), pp. 88-136
[7.]
The Scandinavian Simvastatin Survival Study, (4S).
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet, 344 (1994), pp. 1383-1389
[8.]
The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
N Engl J Med, 339 (1998), pp. 1349-1357
[9.]
F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, et al.
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
N Engl J Med, 335 (1996), pp. 1001-1009
[10.]
F.M. Sacks, A.M. Tonkin, J. Shepherd, E. Braunwald, S. Cobbe, C.M. Hawkins, et al.
Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project.
Circulation, 102 (2000), pp. 1893-1900
[11.]
Heart Protection Study Collaborative Group.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. A randomised placebo-controlled trial.
Lancet, 360 (2002), pp. 7-22
[12.]
The ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group.
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
JAMA, 288 (2002), pp. 2998-3007
[13.]
P.S. Sever, B. Dahlöf, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield, et al.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have ave- rage or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Lancet, 361 (2003), pp. 1149-1158
[14.]
J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, P.W. MacFarlane, et al.
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
N Engl J Med, 333 (1995), pp. 1301-1307
[15.]
J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, et al.
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels Results of AFCAPS/TexCAPS.
JAMA, 279 (1998), pp. 1615-1622
[16.]
J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, S.M. Cobbe, et al.
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.
Lancet, 360 (2002), pp. 1623-1630
[17.]
R. Collins, J. Armitage, S. Parish, P. Sleigh, R. Peto, Heart Protection Study Collaborative Group.
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
Lancet, 361 (2003), pp. 2005-2016
[18.]
C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino, et al.
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins.
Lancet, 366 (2005), pp. 1267-1278
[19.]
P.M. Kearney, L. Blackwell, R. Collins, A. Keech, J. Simes, Cholesterol Treatment Trialists’ (CTT) Collaborators, et al.
Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
Lancet, 371 (2008), pp. 117-125
[20.]
C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, et al.
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
N Engl J Med, 350 (2004), pp. 1495-1504
[21.]
J.C. LaRosa, S.M. Grundy, D.D. Waters, C. Shear, P. Barter, J.C. Fruchart, et al.
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
N Engl J Med, 352 (2005), pp. 1425-1435
[22.]
U. Ravnskov, P.J. Rosch, M.C. Sutter, M.C. Houston.
Should we lower cholesterol as much as possible?.
BMJ, 332 (2006), pp. 1330-1332
[23.]
D.D. Waters.
Safety of high-dose atorvastatin therapy.
Am J Cardiol, 96 (2005), pp. 69-75
[24.]
J. Armitage.
The safety of statins in clinical practice.
Lancet, 370 (2007), pp. 1781-1790
[25.]
C.M. Ballantyne, A. Corsini, M.H. Davidson, H. Holdaas, T.A. Jacobson, E. Leitersdorf, et al.
Risk for myopathy with statin therapy in high-risk patients.
Arch Intern Med, 163 (2003), pp. 553-564
[26.]
P. Amarenco, J. Bogousslavsky, A. Callahan 3rd, L.B. Goldstein, M. Hennerici, A.E. Rudolph, et al.
High-dose atorvastatin after stroke or transient ischemic attack.
N Engl J Med, 355 (2006), pp. 549-559
[27.]
E.J. Stanek, C. Sarawate, V.J. Willey, S.L. Charland, M.J. Cziraky.
Risk of cardiovascular events in patients at optimal values for combined lipid parameters.
Curr Med Res Opin, 23 (2007), pp. 553-563
[28.]
R.A. Hayward, T.P. Hofer, S. Vijan.
Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem.
Ann Intern Med, 145 (2006), pp. 520-530
[29.]
S. Yusuf, S. Hawken, S. Ounpuu, T. Dans, A. Avezum, F. Lanas, et al.
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study.
Lancet, 364 (2004), pp. 937-952
[30.]
A.A. Alsheikh-Ali, J.L. Lin, P. Abourjaily, D. Ahearn, J.T. Kuvin, R.H. Karas.
Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary high disease or risk equivalent and controlled low-density lipoprotein cholesterol.
Am J Cardiol, 100 (2007), pp. 1499-1501
[31.]
J. Ferrières, M. Elbaz, E. Maupas, D. Carriè, J. Puel.
Inadequate management of dyslipidaemic patients in France Results of the Odyssée study.
Arch Mal Coeur, 97 (2004), pp. 187-193
[32.]
M.D. Carroll, D.A. Lacher, P.D. Sorlie, J.I. Cleeman, D.J. Gordon, M. Wolz, et al.
Trends in serum lipids and lipoproteins of adults, 1960–2002.
JAMA, 294 (2005), pp. 1773-1781
[33.]
C.A. Sarawate, M.J. Cziraky, E.J. Stanek, V.J. Willey, J.C. Corbelli, S.L. Charland.
Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?.
Clin Ther, 29 (2007), pp. 196-209
[34.]
S. Bansal, J.E. Buring, N. Rifai, S. Mora, F.M. Sacks, P.M. Ridker.
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women.
JAMA, 298 (2007), pp. 309-316
[35.]
B.G. Nordestgaard, M. Benn, P. Schnohr, A. Tybjaerg-Hansen.
Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.
JAMA, 297 (2007), pp. 299-308
[36.]
T. Gordon, W.P. Castelli, M.C. Hjortland, W.B. Kannel, T.R. Dawber.
High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.
Am J Med, 62 (1977), pp. 707-714
[37.]
G. Assmann, P. Cullen, H. Schulte.
Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the PROCAM Study.
Circulation, 105 (2002), pp. 310-315
[38.]
D.J. Gordon, J.L. Probstfield, R.J. Garrison, J.D. Neaton, W.P. Castelli, J.D. Knoke, et al.
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Circulation, 79 (1989), pp. 8-15
[39.]
A.R. Sharrett, C.M. Ballantyne, S.A. Coady, G. Heiss, P.D. Sorlie, D. Catellier, et al.
Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions. The Atherosclerosis Risk in Communities (ARIC) study.
Circulation, 104 (2001), pp. 1108-1113
[40.]
A.W.E. Weverling-Rijnsburger, I.J.A.M. Jonkers, E. van Exel, J. Gussekloo, R.G.J. Westendorp.
High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age.
Arch Intern Med, 163 (2003), pp. 1549-1554
[41.]
N. Sarwar, J. Danesh, G. Eiriksdottir, G. Sigurdsson, N. Wareham, S. Bingham, et al.
Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies.
Circulation, 115 (2007), pp. 450-458
[42.]
G. Assmann, H. Schulte.
Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience).
Am J Cardiol, 70 (1992), pp. 733-737
[43.]
G. Assmann, H. Schulte, A. von Eckardstein.
Hypertriglyceride- mia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men.
Am J Cardiol, 77 (1996), pp. 1179-1184
[44.]
V. Manninen, L. Tenkanen, P. Koskinen, J.K. Huttunen, M. Mänttäri, O.P. Heinonen, et al.
Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
Circulation, 85 (1992), pp. 37-45
[45.]
M. Arca, A. Montali, S. Valiante, F. Campagna, G. Pigna, V. Paoletti, et al.
Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease.
Am J Cardiol, 100 (2007), pp. 1511-1516
[46.]
J.K. Ninomiya, G. L’Italien, M.H. Criqui, J.L. Whyte, A. Gamst, R.S. Chen.
Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey.
Circulation, 109 (2004), pp. 42-46
[47.]
F.M. Sacks, A.M. Tonkin, T. Craven, M.A. Pfeffer, J. Shepherd, A. Keech, et al.
Coronary heart disease in patients with low LDL-cholesterol. Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors.
Circulation, 105 (2002), pp. 1424-1428
[48.]
P. Barter, A.M. Gotto, J.C. LaRosa, J. Maroni, M. Szarek, S.M. Grundy, et al.
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
N Engl J Med, 357 (2007), pp. 1301-1310
[49.]
M. Miller, C.P. Cannon, S.A. Murphy, J. Qin, K.K. Ray, E. Braunwald, et al.
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE-IT TIMI 22 trial.
J Am Coll Cardiol, 51 (2008), pp. 724-730
[50.]
E. Bruckert, M. Baccara-Dinet, E. Eschwege.
Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey.
Diabet Med, 24 (2007), pp. 388-391
[51.]
I. Goldenberg, M. Benderly, R. Sidi, V. Boyko, A. Tenenbaum, D. Tanne, et al.
Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Am J Cardiol, 103 (2009), pp. 41-45
[52.]
A. Keech, R.J. Simes, P. Barter, J. Best, R. Scott, M.R. Taskinen, et al.
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Lancet, 366 (2005), pp. 1849-1861
[53.]
A.M. Tonkin, L. Chen.
Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Circulation, 122 (2010), pp. 850-852
[54.]
J.C. Fruchart, F.M. Sacks, M.P. Hermans, International Steering Committee of R(3)i.
Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i).
Curr Med Res Opin, 26 (2010), pp. 1793-1797
Copyright © 2011. Sociedad Española de Endocrinología y Nutrición